Cyclacel Pharmaceuticals Current Ratio 2006-2021 | CYCC

Cyclacel Pharmaceuticals current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Cyclacel Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.05B $0.00B 14.82
2021-03-31 $0.05B $0.00B 18.21
2020-12-31 $0.04B $0.00B 14.27
2020-09-30 $0.03B $0.00B 15.15
2020-06-30 $0.03B $0.00B 18.47
2020-03-31 $0.01B $0.00B 7.76
2019-12-31 $0.01B $0.00B 5.79
2019-09-30 $0.02B $0.00B 7.65
2019-06-30 $0.02B $0.00B 7.26
2019-03-31 $0.02B $0.00B 8.09
2018-12-31 $0.02B $0.00B 4.45
2018-09-30 $0.02B $0.00B 5.16
2018-06-30 $0.02B $0.00B 5.68
2018-03-31 $0.03B $0.00B 5.81
2017-12-31 $0.03B $0.00B 6.32
2017-09-30 $0.03B $0.00B 6.52
2017-06-30 $0.02B $0.00B 3.72
2017-03-31 $0.02B $0.00B 4.13
2016-12-31 $0.02B $0.01B 3.73
2016-09-30 $0.02B $0.01B 4.05
2016-06-30 $0.02B $0.01B 3.37
2016-03-31 $0.02B $0.01B 3.95
2015-12-31 $0.03B $0.01B 4.27
2015-09-30 $0.03B $0.01B 5.09
2015-06-30 $0.03B $0.01B 4.70
2015-03-31 $0.04B $0.01B 4.31
2014-12-31 $0.03B $0.01B 3.87
2014-09-30 $0.03B $0.01B 4.61
2014-06-30 $0.04B $0.01B 4.79
2014-03-31 $0.03B $0.01B 3.80
2013-12-31 $0.04B $0.01B 4.85
2013-09-30 $0.04B $0.01B 4.20
2013-06-30 $0.04B $0.01B 5.65
2013-03-31 $0.02B $0.01B 2.35
2012-12-31 $0.02B $0.01B 2.02
2012-09-30 $0.02B $0.01B 2.73
2012-06-30 $0.02B $0.01B 3.21
2012-03-31 $0.03B $0.01B 3.70
2011-12-31 $0.03B $0.01B 3.98
2011-09-30 $0.03B $0.01B 4.85
2011-06-30 $0.02B $0.01B 3.72
2011-03-31 $0.03B $0.01B 3.94
2010-12-31 $0.03B $0.01B 4.75
2010-09-30 $0.02B $0.01B 2.47
2010-06-30 $0.02B $0.01B 2.64
2010-03-31 $0.03B $0.01B 2.72
2009-12-31 $0.01B $0.01B 1.56
2009-09-30 $0.02B $0.01B 1.74
2009-06-30 $0.02B $0.01B 1.68
2009-03-31 $0.02B $0.01B 2.74
2008-12-31 $0.03B $0.01B 3.36
2008-09-30 $0.04B $0.01B 3.78
2008-06-30 $0.05B $0.01B 3.94
2008-03-31 $0.05B $0.01B 4.86
2007-12-31 $0.06B $0.02B 4.34
2007-09-30 $0.08B $0.01B 6.90
2007-06-30 $0.08B $0.01B 6.89
2007-03-31 $0.09B $0.01B 12.96
2006-12-31 $0.06B $0.01B 7.34
2006-09-30 $0.06B $0.01B 9.67
2006-06-30 $0.07B $0.01B 9.89
2006-03-31 $0.03B $0.01B 3.11
2005-12-31 $0.02B $0.02B 1.15
2005-09-30 $0.03B $0.01B 3.26
2005-06-30 $0.03B $0.01B 5.70
2005-03-31 $0.04B $0.01B 5.46
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.046B $0.000B
CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76